{ "instance": { "thct_10q.htm": { "axisCustom": 0, "axisStandard": 11, "contextCount": 213, "dts": { "calculationLink": { "local": [ "thct-20220430_cal.xml" ] }, "definitionLink": { "local": [ "thct-20220430_def.xml" ] }, "inline": { "local": [ "thct_10q.htm" ] }, "labelLink": { "local": [ "thct-20220430_lab.xml" ] }, "presentationLink": { "local": [ "thct-20220430_pre.xml" ] }, "schema": { "local": [ "thct-20220430.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 336, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 46, "http://thctherapeutics.com/20220430": 8, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 59 }, "keyCustom": 64, "keyStandard": 155, "memberCustom": 51, "memberStandard": 6, "nsprefix": "thct", "nsuri": "http://thctherapeutics.com/20220430", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://thctherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "thct:PhysicalSilverAssetstextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - PHYSICAL SILVER ASSETS", "role": "http://thctherapeutics.com/role/PhysicalSilverAssets", "shortName": "PHYSICAL SILVER ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "thct:PhysicalSilverAssetstextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - FIXED ASSETS", "role": "http://thctherapeutics.com/role/FixedAssets", "shortName": "FIXED ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - INTANGIBLE ASSETS", "role": "http://thctherapeutics.com/role/IntangibleAssets", "shortName": "INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://thctherapeutics.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "thct:NotesPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - NOTES PAYABLE", "role": "http://thctherapeutics.com/role/NotesPayable", "shortName": "NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "thct:NotesPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "thct:ConvertibleNotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - CONVERTIBLE NOTES PAYABLE", "role": "http://thctherapeutics.com/role/ConvertibleNotesPayable", "shortName": "CONVERTIBLE NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "thct:ConvertibleNotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://thctherapeutics.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "thct:StockWarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - STOCK WARRANTS", "role": "http://thctherapeutics.com/role/StockWarrants", "shortName": "STOCK WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "thct:StockWarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - SHAREHOLDERS DEFICIT", "role": "http://thctherapeutics.com/role/ShareholdersDeficit", "shortName": "SHAREHOLDERS DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - SUBSEQUENT EVENTS", "role": "http://thctherapeutics.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://thctherapeutics.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Policies)", "role": "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Tables)", "role": "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - FIXED ASSETS (Tables)", "role": "http://thctherapeutics.com/role/FixedAssetsTables", "shortName": "FIXED ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - INTANGIBLE ASSETS (Tables)", "role": "http://thctherapeutics.com/role/IntangibleAssetsTables", "shortName": "INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)", "role": "http://thctherapeutics.com/role/RelatedPartyTransactionsTables", "shortName": "RELATED PARTY TRANSACTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "thct:NotesPayableDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "thct:NotesPayableTabeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - NOTES PAYABLE (Tables)", "role": "http://thctherapeutics.com/role/NotesPayableTables", "shortName": "NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "thct:NotesPayableDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "thct:NotesPayableTabeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "thct:ConvertibleNotesPayableTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables)", "role": "http://thctherapeutics.com/role/ConvertibleNotesPayableTables", "shortName": "CONVERTIBLE NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "thct:ConvertibleNotesPayableTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "thct:StockWarrantsTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - STOCK WARRANTS (Tables)", "role": "http://thctherapeutics.com/role/StockWarrantsTables", "shortName": "STOCK WARRANTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "thct:StockWarrantsTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - BASIS OF PRESENTATION AND GOING CONCERN (Details Narrative)", "role": "http://thctherapeutics.com/role/BasisOfPresentationAndGoingConcernDetailsNarrative", "shortName": "BASIS OF PRESENTATION AND GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "thct:PhysicalSilverAssets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Details )", "role": "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetails", "shortName": "SUMMARY OF SIGNIFICANT POLICIES (Details )", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "lang": null, "name": "us-gaap:DerivativeInstrumentsAndHedgesLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://thctherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30_thct_PreferredBStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "thct:BeginningBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Details 1)", "role": "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetails1", "shortName": "SUMMARY OF SIGNIFICANT POLICIES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "thct:BeginningBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Details Narrative)", "role": "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-01-31", "decimals": "INF", "lang": null, "name": "thct:VolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "thct:PhysicalSilverAssets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - PHYSICAL SILVER ASSETS (Details Narrative)", "role": "http://thctherapeutics.com/role/PhysicalSilverAssetsDetailsNarrative", "shortName": "PHYSICAL SILVER ASSETS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - FIXED ASSETS (Details)", "role": "http://thctherapeutics.com/role/FixedAssetsDetails", "shortName": "FIXED ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - FIXED ASSETS (Details Narrative)", "role": "http://thctherapeutics.com/role/FixedAssetsDetailsNarrative", "shortName": "FIXED ASSETS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - INTANGIBLE ASSETS (Details)", "role": "http://thctherapeutics.com/role/IntangibleAssetsDetails", "shortName": "INTANGIBLE ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AdjustmentForAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - INTANGIBLE ASSETS (Details Narrative)", "role": "http://thctherapeutics.com/role/IntangibleAssetsDetailsNarrative", "shortName": "INTANGIBLE ASSETS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AdjustmentForAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30_thct_PrincipalMember", "decimals": "0", "first": true, "lang": null, "name": "thct:BRomanekPresidentAndCeo", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "role": "http://thctherapeutics.com/role/RelatedPartyTransactionsDetails", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30_thct_PrincipalMember", "decimals": "0", "first": true, "lang": null, "name": "thct:BRomanekPresidentAndCeo", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000038 - Disclosure - RELATED PARTY TRANSACTIONS (Details 1)", "role": "http://thctherapeutics.com/role/RelatedPartyTransactionsDetails1", "shortName": "RELATED PARTY TRANSACTIONS (Details 1)", "subGroupType": "details", "uniqueAnchor": null }, "R39": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "thct:InitialLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000039 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "thct:InitialLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2022-02-01to2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS", "role": "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations", "shortName": "CONSOLIDATED STATEMENT OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2022-02-01to2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "thct:NotesPayableDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000040 - Disclosure - NOTES PAYABLE (Details)", "role": "http://thctherapeutics.com/role/NotesPayableDetails", "shortName": "NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "p", "thct:NotesPayableDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000041 - Disclosure - NOTES PAYABLE (Details Narrative)", "role": "http://thctherapeutics.com/role/NotesPayableDetailsNarrative", "shortName": "NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "thct:NotesPayableDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30", "decimals": "INF", "lang": null, "name": "thct:PromissoryNoteRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "thct:ConvertibleNotesPayableTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30_thct_ConvertibleNotesPayableOneMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleNotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000042 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details)", "role": "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails", "shortName": "CONVERTIBLE NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "thct:ConvertibleNotesPayableTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30_thct_ConvertibleNotesPayableOneMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleNotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000043 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details 1)", "role": "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails1", "shortName": "CONVERTIBLE NOTES PAYABLE (Details 1)", "subGroupType": "details", "uniqueAnchor": null }, "R44": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "INF", "first": true, "lang": null, "name": "thct:OutstandingNoteBalancesPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://thctherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "INF", "first": true, "lang": null, "name": "thct:OutstandingNoteBalancesPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "thct:StockWarrantsTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30_thct_WarrantsMember", "decimals": "0", "first": true, "lang": null, "name": "thct:WarrantsOutstandingBeginningBalance", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000045 - Disclosure - STOCK WARRANTS (Details)", "role": "http://thctherapeutics.com/role/StockWarrantsDetails", "shortName": "STOCK WARRANTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "thct:StockWarrantsTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30_thct_WarrantsMember", "decimals": "0", "first": true, "lang": null, "name": "thct:WarrantsOutstandingBeginningBalance", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2022-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000046 - Disclosure - SHAREHOLDERS DEFICIT (Details Narrative)", "role": "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative", "shortName": "SHAREHOLDERS DEFICIT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2017-01-24_thct_SeriesAPreferredStocksMember", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2019-07-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY", "role": "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "AsOf2019-07-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS", "role": "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows", "shortName": "CONSOLIDATED STATEMENT OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY", "role": "http://thctherapeutics.com/role/DescriptionOfBusinessAndHistory", "shortName": "DESCRIPTION OF BUSINESS AND HISTORY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - BASIS OF PRESENTATION AND GOING CONCERN", "role": "http://thctherapeutics.com/role/BasisOfPresentationAndGoingConcern", "shortName": "BASIS OF PRESENTATION AND GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES", "role": "http://thctherapeutics.com/role/SummaryOfSignificantPolicies", "shortName": "SUMMARY OF SIGNIFICANT POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "thct_10q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 57, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://thctherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r132", "r279" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_AccruedInterestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Interest [Member]" } } }, "localname": "AccruedInterestMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "thct_AdvancesDueWithinDays": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Advances Due Within, Days" } } }, "localname": "AdvancesDueWithinDays", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "integerItemType" }, "thct_AdvancesFromRelatedParties": { "auth_ref": [], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Advances from related parties" } } }, "localname": "AdvancesFromRelatedParties", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "thct_AgeementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ageement [Member]" } } }, "localname": "AgeementMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_AugustNineteenTwoZeroTwoOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "August 19, 2021 [Member]" } } }, "localname": "AugustNineteenTwoZeroTwoOneMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_AugustNineteenTwoZeroTwoOneOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "August 19, 2021 (1) [Member]" } } }, "localname": "AugustNineteenTwoZeroTwoOneOneMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_AugustNineteenTwoZeroTwoOneTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "August 19, 2021 (2) [Member]" } } }, "localname": "AugustNineteenTwoZeroTwoOneTwoMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_AugustSixteenTwoZeroTwoOneOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "August 16, 2021 (1) [Member]" } } }, "localname": "AugustSixteenTwoZeroTwoOneOneMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_AugustSixteenTwoZeroTwoOneTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "August 16, 2021 (2) [Member]" } } }, "localname": "AugustSixteenTwoZeroTwoOneTwoMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_AugustTwentySixTwoZeroTwoOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "August 26, 2021 [Member]" } } }, "localname": "AugustTwentySixTwoZeroTwoOneMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_AugustTwentySixTwoZeroTwoOneOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "August 26, 2021 (1) [Member]" } } }, "localname": "AugustTwentySixTwoZeroTwoOneOneMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_AutomobileMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "dHydronator prototype [Member]" } } }, "localname": "AutomobileMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/FixedAssetsDetails" ], "xbrltype": "domainItemType" }, "thct_BRomanekPresidentAndCeo": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "B. Romanek, President And Ceo" } } }, "localname": "BRomanekPresidentAndCeo", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "thct_BeginningBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Beginning Balance" } } }, "localname": "BeginningBalance", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "thct_CashProceedsOfstockissued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cash proceeds" } } }, "localname": "CashProceedsOfstockissued", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "thct_CashReceivedForStockPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cash received for stock" } } }, "localname": "CashReceivedForStockPayable", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "thct_ChiefExecutiveOfficersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficersMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_CommonStockValueofstockissued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common Stock Value Of Stock Issued" } } }, "localname": "CommonStockValueofstockissued", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "thct_CommonstocksharesCancelled": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Cancelled" } } }, "localname": "CommonstocksharesCancelled", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "thct_CommonstocksharesRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Repurchased" } } }, "localname": "CommonstocksharesRepurchased", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "thct_ConsultingFees": { "auth_ref": [], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Consulting fees" } } }, "localname": "ConsultingFees", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "thct_ConversionOfPreferredSharesIntoCommonStockSharesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of preferred shares into common stock shares, amount" } } }, "localname": "ConversionOfPreferredSharesIntoCommonStockSharesAmount", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "thct_ConversionOfPreferredSharesIntoCommonStockSharesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion of preferred shares into common stock shares, shares" } } }, "localname": "ConversionOfPreferredSharesIntoCommonStockSharesShares", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "thct_ConvertibleNotesPayableOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Note One [Member]" } } }, "localname": "ConvertibleNotesPayableOneMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "thct_ConvertibleNotesPayableRelatedPartyNet": { "auth_ref": [], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible notes payable- related party" } } }, "localname": "ConvertibleNotesPayableRelatedPartyNet", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "thct_ConvertibleNotesPayableSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Note Six [Member]" } } }, "localname": "ConvertibleNotesPayableSixMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "thct_ConvertibleNotesPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "9. Convertible Notes Payable" } } }, "localname": "ConvertibleNotesPayableTextBlock", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayable" ], "xbrltype": "textBlockItemType" }, "thct_ConvertibleNotesPayableTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Note Two [Member]" } } }, "localname": "ConvertibleNotesPayableTwoMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "thct_ConvertiblePromissoryNoteFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Note Five [Member]" } } }, "localname": "ConvertiblePromissoryNoteFiveMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "thct_ConvertiblePromissoryNoteFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Note Four [Member]" } } }, "localname": "ConvertiblePromissoryNoteFourMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "thct_ConvertiblePromissoryNoteThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Note Three [Member]" } } }, "localname": "ConvertiblePromissoryNoteThreeMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "thct_DecemberSeventeenTwoZeroTwoOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "December 17, 2021 [Member]" } } }, "localname": "DecemberSeventeenTwoZeroTwoOneMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_DerivativeLiabilityWrittenOffToAdditionalPaidInCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Derivative liability written off to additional paid in capital" } } }, "localname": "DerivativeLiabilityWrittenOffToAdditionalPaidInCapital", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "thct_DerivativeWrittenOffToAdditionalPaidInCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Derivative written off to additional paid in capital" } } }, "localname": "DerivativeWrittenOffToAdditionalPaidInCapital", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "thct_DueDateOfNote": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Due date of note" } } }, "localname": "DueDateOfNote", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "dateItemType" }, "thct_EndingBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Ending Balance" } } }, "localname": "EndingBalance", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "thct_EquipmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Float Spa and associated equipment [Member]" } } }, "localname": "EquipmentsMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/FixedAssetsDetails" ], "xbrltype": "domainItemType" }, "thct_FairValueOfStockIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Fair Value Of Stock Issued" } } }, "localname": "FairValueOfStockIssued", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "thct_FebruaryFifteenTwoZeroTwoOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "November Fifteen, 2021 [Member]" } } }, "localname": "FebruaryFifteenTwoZeroTwoOneMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_FebruaryTenSixteenTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "February 10, 2022 [Member]" } } }, "localname": "FebruaryTenSixteenTwoThousandTwentyTwoMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_FebruaryTenTwentyTwentyTwoOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "February 10, 2022 (1) [Member]" } } }, "localname": "FebruaryTenTwentyTwentyTwoOneMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_FebruaryTenTwoZeroTwentyTwoTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "February 10, 2022 (2) [Member]" } } }, "localname": "FebruaryTenTwoZeroTwentyTwoTwoMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_FebruaryTwoTwoZeroTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Februrary 2, 2022 [Member]" } } }, "localname": "FebruaryTwoTwoZeroTwentyTwoMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_FundsAdvanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Funds Advance [Member]" } } }, "localname": "FundsAdvanceMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "thct_FundsRepaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Funds Repaid [Member]" } } }, "localname": "FundsRepaidMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "thct_IncreaseDecreaseInFairMarketValueDerivativeLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Change In Fair Market Value Of Derivative Liabilities" } } }, "localname": "IncreaseDecreaseInFairMarketValueDerivativeLiabilities", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "thct_InitialLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Initial Loss" } } }, "localname": "InitialLoss", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "thct_LevelOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Level 1 [Member]" } } }, "localname": "LevelOneMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "domainItemType" }, "thct_LevelThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Level 3 [Member]" } } }, "localname": "LevelThreeMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "domainItemType" }, "thct_LevelTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Level 2 [Member]" } } }, "localname": "LevelTwoMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "domainItemType" }, "thct_LowestVwapPriceEqualPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lowest Vwap Price Equal" } } }, "localname": "LowestVwapPriceEqualPercentage", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "thct_MayOneTwoThousandNinteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "May 1, 2019 [Member]" } } }, "localname": "MayOneTwoThousandNinteenMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_MrRomanekMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mr. Romanek [Member]" } } }, "localname": "MrRomanekMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_NotesPayableDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "8.Notes Payable" } } }, "localname": "NotesPayableDisclosureTextBlock", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "thct_NotesPayableTabeTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Notes Payable" } } }, "localname": "NotesPayableTabeTextBlock", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "thct_NovemberEighteenTwoZeroTwoOneOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "November 18, 2021 (1) [Member]" } } }, "localname": "NovemberEighteenTwoZeroTwoOneOneMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_NovemberFiveTwoZeroTwoOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "November 5, 2021 [Member]" } } }, "localname": "NovemberFiveTwoZeroTwoOneMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_OutstandingNoteBalancesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding note balances, percentage" } } }, "localname": "OutstandingNoteBalancesPercentage", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "thct_PatentsAndPatentsPendingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Patents and Patents Pending [Member]" } } }, "localname": "PatentsAndPatentsPendingMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "thct_PhysicalSilverAssets": { "auth_ref": [], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Physical silver assets", "terseLabel": "Physical Silver Assets", "verboseLabel": "Physical Silver Assets" } } }, "localname": "PhysicalSilverAssets", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets", "http://thctherapeutics.com/role/PhysicalSilverAssetsDetailsNarrative", "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "thct_PhysicalSilverAssetstextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "4. Physical Silver Assets" } } }, "localname": "PhysicalSilverAssetstextblock", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/PhysicalSilverAssets" ], "xbrltype": "textBlockItemType" }, "thct_PreferredAOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred A [Member]" } } }, "localname": "PreferredAOneMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_PreferredAStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred A Stocks [Member]" } } }, "localname": "PreferredAStocksMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "thct_PreferredBStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred B Stock [Member]" } } }, "localname": "PreferredBStockMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets", "http://thctherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "thct_PreferredBStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred B Stocks [Member]" } } }, "localname": "PreferredBStocksMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "thct_PreferredCStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred C Stock [Member]" } } }, "localname": "PreferredCStockMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets", "http://thctherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "thct_PreferredCStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred C Stock, Shares Issued" } } }, "localname": "PreferredCStockSharesIssued", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "thct_PreferredCStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred C Stocks [Member]" } } }, "localname": "PreferredCStocksMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "thct_PreferredsClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred A Stock [Member]" } } }, "localname": "PreferredsClassAMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "thct_PrincipalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Principal [Member]" } } }, "localname": "PrincipalMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "thct_PromissoryNoteRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory note rate" } } }, "localname": "PromissoryNoteRate", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "thct_PurchaseOfSilver": { "auth_ref": [], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Purchase of silver]", "negatedLabel": "Purchase of silver" } } }, "localname": "PurchaseOfSilver", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "thct_RepurchaseOfCommonStockAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Repurchase of common stock, amount" } } }, "localname": "RepurchaseOfCommonStockAmount", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "thct_RepurchaseOfCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Repurchase of common stock, shares" } } }, "localname": "RepurchaseOfCommonStockShares", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "thct_RiskFreeDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risk-free Discount Rate" } } }, "localname": "RiskFreeDiscountRate", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "thct_ScheduleForDerivativesLiabilitiesOfIssuanceOfTheConvertibleNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule For Derivatives Liabilities Of Issuance Of The Convertible Notes" } } }, "localname": "ScheduleForDerivativesLiabilitiesOfIssuanceOfTheConvertibleNotes", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "thct_SeptemberThirteenTwoZeroTwoOneOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "September 13, 2021 (1) [Member]" } } }, "localname": "SeptemberThirteenTwoZeroTwoOneOneMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_SeptemberThirteenteenTwoZeroTwoOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "September 13, 2021 [Member]" } } }, "localname": "SeptemberThirteenteenTwoZeroTwoOneMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_SeriesAPreferredStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStocksMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_SeriesBPreferredStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStocksMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_SeriesCPreferredStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStocksMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "thct_ShareholderRelativeOfOurPresidentAndCeo": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Shareholder Relative Of Our President And Ceo" } } }, "localname": "ShareholderRelativeOfOurPresidentAndCeo", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "thct_SharesAndWarrantsIssuedForServicesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares and warrants issued for services, amount" } } }, "localname": "SharesAndWarrantsIssuedForServicesAmount", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "thct_SharesAndWarrantsIssuedForServicesShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares and warrants issued for services" } } }, "localname": "SharesAndWarrantsIssuedForServicesShares", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "thct_SharesCancelledAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares cancelled, amount" } } }, "localname": "SharesCancelledAmount", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "thct_SharesCancelledShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares cancelled, shares" } } }, "localname": "SharesCancelledShares", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "thct_SharesIssuedForCashAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued for cash, amount" } } }, "localname": "SharesIssuedForCashAmount", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "thct_SharesIssuedForCashShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued for cash, shares" } } }, "localname": "SharesIssuedForCashShares", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "thct_SharesIssuedForConversionOfConvertibleDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Shares issued for conversion of convertible debt, amount" } } }, "localname": "SharesIssuedForConversionOfConvertibleDebtAmount", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "thct_SharesIssuedForConversionOfConvertibleDebtShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued for conversion of convertible debt, shares" } } }, "localname": "SharesIssuedForConversionOfConvertibleDebtShares", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "thct_SharesIssuedForServicesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued for services, amount" } } }, "localname": "SharesIssuedForServicesAmount", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "thct_SharesIssuedForServicesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued for services, shares" } } }, "localname": "SharesIssuedForServicesShares", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "thct_StockIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock issued for services" } } }, "localname": "StockIssuedForServices", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "thct_StockPayable": { "auth_ref": [], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Stock payable" } } }, "localname": "StockPayable", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "thct_StockPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Payable [Member]" } } }, "localname": "StockPayableMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "thct_StockPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Price" } } }, "localname": "StockPrice", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "thct_StockReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Receivable [Member]" } } }, "localname": "StockReceivableMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "thct_StockReceivables": { "auth_ref": [], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Stock receivable" } } }, "localname": "StockReceivables", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "thct_StockWarrantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "11. Stock Warrants" } } }, "localname": "StockWarrantsTextBlock", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/StockWarrants" ], "xbrltype": "textBlockItemType" }, "thct_TOTAL": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Total]", "verboseLabel": "Total" } } }, "localname": "TOTAL", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "thct_TrademarkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trademarks [Member]" } } }, "localname": "TrademarkMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "thct_TradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trading Days" } } }, "localname": "TradingDays", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "durationItemType" }, "thct_VariableConversionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Variable Conversion Rate" } } }, "localname": "VariableConversionRate", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "thct_VariableConversionRateEqualToStatedPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Variable Conversion Rate Equal To Stated Price, Per Share" } } }, "localname": "VariableConversionRateEqualToStatedPrice", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "thct_VolatilityRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Volatility" } } }, "localname": "VolatilityRate", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "thct_WarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Exercised" } } }, "localname": "WarrantsExercised", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/StockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "thct_WarrantsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Expired" } } }, "localname": "WarrantsExpired", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/StockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "thct_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/StockWarrantsDetails" ], "xbrltype": "domainItemType" }, "thct_WarrantsOutstandingBeginningBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Outstanding, Beginning Balance" } } }, "localname": "WarrantsOutstandingBeginningBalance", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/StockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "thct_WarrantsOutstandingEndingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Outstanding, Ending Balance" } } }, "localname": "WarrantsOutstandingEndingBalance", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/StockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "thct_WeightedAverageExercisePriceBeginningBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Beginning Balance" } } }, "localname": "WeightedAverageExercisePriceBeginningBalance", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/StockWarrantsDetails" ], "xbrltype": "perShareItemType" }, "thct_WeightedAverageExercisePriceEndingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Ending Balance" } } }, "localname": "WeightedAverageExercisePriceEndingBalance", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/StockWarrantsDetails" ], "xbrltype": "perShareItemType" }, "thct_WeightedAverageExercisePriceWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Warrants Exercised" } } }, "localname": "WeightedAverageExercisePriceWarrantsExercised", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/StockWarrantsDetails" ], "xbrltype": "perShareItemType" }, "thct_WeightedAverageExercisePriceWarrantsGrantedAndAssumed": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Warrants Granted And Assumed" } } }, "localname": "WeightedAverageExercisePriceWarrantsGrantedAndAssumed", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/StockWarrantsDetails" ], "xbrltype": "perShareItemType" }, "thct_convertedshares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Converted shares" } } }, "localname": "convertedshares", "nsuri": "http://thctherapeutics.com/20220430", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DESCRIPTION OF BUSINESS AND HISTORY" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT POLICIES" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r23", "r75", "r278", "r280" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses - related party" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r22", "r153" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]", "negatedLabel": "Less: Accumulated Depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/FixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r15", "r217", "r285" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r77", "r78", "r79", "r214", "r215", "r216", "r249" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r62", "r146" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization Expense" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "[Adjustments to Additional Paid in Capital, Other]", "negatedLabel": "Derivative Reclassed To Additional Paid In Capital" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expenses" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r53", "r62", "r178", "r271" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount", "verboseLabel": "Debt Discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows", "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r74", "r118", "r121", "r127", "r134", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r175", "r176", "r231", "r235", "r262", "r283", "r285", "r307", "r318" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r35", "r74", "r134", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r175", "r176", "r231", "r235", "r262", "r283", "r285" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FIXED ASSETS (Tables)" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r205", "r213" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative", "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative", "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "2. Basis Of Presentation And Going Concern" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/BasisOfPresentationAndGoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PHYSICAL SILVER ASSETS" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r76", "r114" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "1. Description Of Business And History" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/DescriptionOfBusinessAndHistory" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r20", "r64" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "periodEndLabel": "Ending cash balance", "periodStartLabel": "Beginning cash balance" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets", "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r8", "r65" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash And Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r59", "r263" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]", "totalLabel": "Net decrease in Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r20" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "[Cash Equivalents, at Carrying Value]", "terseLabel": "Cash", "verboseLabel": "Cash" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/BasisOfPresentationAndGoingConcernDetailsNarrative", "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r72", "r74", "r91", "r92", "r93", "r95", "r97", "r103", "r104", "r105", "r134", "r164", "r169", "r170", "r171", "r175", "r176", "r180", "r181", "r183", "r187", "r262", "r342" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets", "http://thctherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative", "http://thctherapeutics.com/role/StockWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r31", "r160", "r310", "r324" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies (See note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r157", "r158", "r159", "r163", "r335" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "10. COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r77", "r78", "r249" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Shares Par Value", "verboseLabel": "Common Stock, Par Value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares Issued", "verboseLabel": "Common Stock, Shares Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r193" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares Outstanding", "verboseLabel": "Common Stock, Shares Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14", "r285" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock; $0.001 par value; 500,000,000 shares authorized;32,491,671 and 29,287,337 shares issued and 33,891,671 and 29,287,337 shares outstanding as of April 30, 2022 and July 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r108", "r317" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r66", "r67", "r68" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Principal Converted Into Preferred Stock" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Net" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE NOTES PAYABLE" } } }, "localname": "ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r11", "r308", "r319", "r332" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible notes payable" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable Current" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockTermsOfConversion": { "auth_ref": [ "r12", "r13", "r194", "r196", "r197", "r198" ], "lang": { "en-us": { "role": { "documentation": "Description of conversion terms for preferred stock.", "label": "Preferred Stock, Terms Of Conversion Feature" } } }, "localname": "ConvertiblePreferredStockTermsOfConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r51", "r74", "r134", "r164", "r165", "r166", "r169", "r170", "r171", "r172", "r173", "r175", "r176", "r262" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentRate": { "auth_ref": [ "r66", "r68" ], "lang": { "en-us": { "role": { "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.", "label": "Advances From Related Parties Bear Interest Rate" } } }, "localname": "DebtConversionConvertedInstrumentRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r66", "r68" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Shares issued for the conversion of debt" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE NOTES PAYABLE (Details 1)" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r29", "r177", "r255" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Due Date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r271", "r273" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Total, Net Of Unamortized Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedPremiumNoncurrent": { "auth_ref": [ "r271", "r273" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of debt premium to be amortized after one year or the normal operating cycle, if longer.", "label": "[Debt Instrument, Unamortized Premium, Noncurrent]", "negatedLabel": "Unamortized Debt Discount" } } }, "localname": "DebtInstrumentUnamortizedPremiumNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r62", "r151" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation Expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/FixedAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r62", "r151" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r244" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations": { "order": 11.0, "parentTag": "us-gaap_OtherNoncashIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Gain (loss) on derivative liability", "negatedLabel": "Loss (gain) on change in derivative liabilities" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows", "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsAndHedgesLiabilities": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum as of the balance sheet date of the (a) fair values of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and (b) the carrying amounts of the liabilities arising from financial instruments or contracts used to mitigate a specified risk (hedge), and which are expected to be extinguished or otherwise disposed of within a year or the normal operating cycle, if longer, net of the effects of master netting arrangements.", "label": "Derivative Financial Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgesLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r36", "r37", "r38", "r261" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r23", "r75", "r167", "r169", "r170", "r174", "r175", "r176", "r277" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due To Related Parties" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS (Tables)" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r48", "r82", "r83", "r84", "r85", "r86", "r90", "r91", "r95", "r96", "r97", "r100", "r101", "r250", "r251", "r312", "r326" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic loss per common share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings (loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SHAREHOLDERS DEFICIT" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r42", "r43", "r44", "r77", "r78", "r79", "r81", "r87", "r89", "r102", "r135", "r193", "r199", "r214", "r215", "r216", "r227", "r228", "r249", "r264", "r265", "r266", "r267", "r268", "r269", "r327", "r328", "r329", "r344" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ExplorationAbandonmentAndImpairmentExpense": { "auth_ref": [ "r62", "r303", "r304", "r305", "r306" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The adjustment to expense previously capitalized costs of drilling exploratory wells when proved reserves are not found or when the entity obtains information that raises substantial doubt about the economic or operational viability of the project.", "label": "Impairment Expense" } } }, "localname": "ExplorationAbandonmentAndImpairmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r252", "r253", "r254", "r257", "r258" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Schedule Of Fair Value Of Assets And Liabilities" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Class of asset." } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r252", "r258" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value Assets And Liabilities Measured On Recurring Basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value Of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r145" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "[Finite-Lived Intangible Assets, Accumulated Amortization]", "negatedLabel": "Less: Accumulated Depreciation" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r140", "r141", "r145", "r147", "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r145", "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r140", "r144" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r145", "r289" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible Assets, Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r138", "r142" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill And Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r50", "r74", "r118", "r120", "r123", "r126", "r128", "r134", "r164", "r165", "r166", "r169", "r170", "r171", "r172", "r173", "r175", "r176", "r262" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations": { "order": 9.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "[Gross Profit]", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r150", "r155" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENT OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r41", "r221", "r222", "r223", "r224", "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r61" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (decrease) in accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r61" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (decrease) in accounts payable related party" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r61" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "[Increase (Decrease) in Prepaid Expense]", "negatedLabel": "Increase (decrease) in prepaid assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "6. Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r139", "r143" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FIXED ASSETS" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r45", "r117", "r270", "r272", "r313" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations": { "order": 10.0, "parentTag": "us-gaap_OtherNoncashIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "[Interest Expense]", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternetDomainNamesMember": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "String of typographic characters used to describe the location of a specific individual, business, computer, or piece of information online. Formally known as the Uniform Resource Locator or URL, it is often considered to be the address of a certain World Wide Web site.", "label": "Website And Domain Names [Member]" } } }, "localname": "InternetDomainNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r34" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r26", "r74", "r122", "r134", "r164", "r165", "r166", "r169", "r170", "r171", "r172", "r173", "r175", "r176", "r232", "r235", "r236", "r262", "r283", "r284" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 25.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r74", "r134", "r262", "r285", "r309", "r322" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "Total liabilities and stockholders' deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r28", "r74", "r134", "r164", "r165", "r166", "r169", "r170", "r171", "r172", "r173", "r175", "r176", "r232", "r235", "r236", "r262", "r283", "r284", "r285" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r160", "r161", "r162" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Monetary damages" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r59" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows provided by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r59" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from investing" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r59", "r60", "r63" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities", "verboseLabel": "Net Cash From Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/BasisOfPresentationAndGoingConcernDetailsNarrative", "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r39", "r40", "r44", "r47", "r63", "r74", "r80", "r82", "r83", "r84", "r85", "r88", "r89", "r94", "r118", "r120", "r123", "r126", "r128", "r134", "r164", "r165", "r166", "r169", "r170", "r171", "r172", "r173", "r175", "r176", "r251", "r262", "r311", "r325" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "terseLabel": "Net Loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/BasisOfPresentationAndGoingConcernDetailsNarrative", "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations", "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r11", "r308", "r320" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes payable, net", "verboseLabel": "Total Notes Payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets", "http://thctherapeutics.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTES PAYABLE" } } }, "localname": "NotesPayableAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Note payable, unsecured, 12% interest, due March 30, 2023", "verboseLabel": "Note payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/NotesPayableDetails", "http://thctherapeutics.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office furniture and equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/FixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations": { "order": 8.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r118", "r120", "r123", "r126", "r128" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations": { "order": 13.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BASIS OF PRESENTATION AND GOING CONCERN" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r63" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations": { "order": 12.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "[Other Noncash Income (Expense)]", "totalLabel": "Total other income (expense)" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCK WARRANTS" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r56" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "[Payments for Repurchase of Common Stock]", "negatedLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r205", "r213" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Preferred Class A [Member]" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Cumulative Dividend Rate" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r13", "r72", "r183", "r194", "r195" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Liquidation Preference Stated Value, Per Share" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "auth_ref": [ "r72", "r183" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.", "label": "Liquidation Preference Stated Value" } } }, "localname": "PreferredStockLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred stock; $0.001 par value; 10,000,000 shares authorized;213,300 and 218,000 series A and B and C shares issued and outstanding as of April 30, 2022 and July 31, 2021, respectively" } } }, "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r13", "r180" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par Value", "verboseLabel": "Preferred Stock, Par Value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionAmount": { "auth_ref": [ "r32", "r179" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.", "label": "Preferred Stock Sold Amount" } } }, "localname": "PreferredStockRedemptionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockShareSubscriptions": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The number of nonredeemable preferred stock (shares) (or preferred stock redeemable solely at the option of the issuer) allocated to investors to buy shares of a new issue of preferred stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Preferred Stock Sold" } } }, "localname": "PreferredStockShareSubscriptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13", "r180" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13", "r285" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred A stock; $0.001 par value; 3,000,000 shares authorized;213,000 and 218,000 shares issued and outstanding as of April 30, 2022 and July 31, 2021, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r6", "r136", "r137" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r54" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r55" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from convertible notes payable", "verboseLabel": "Promissory Note" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows", "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r55" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from related party advances" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfNotesPayable": { "auth_ref": [], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.", "label": "Repayments of convertible notes payable" } } }, "localname": "ProceedsFromRepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r333", "r334" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations": { "order": 7.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r39", "r40", "r44", "r58", "r74", "r80", "r88", "r89", "r118", "r120", "r123", "r126", "r128", "r134", "r164", "r165", "r166", "r169", "r170", "r171", "r172", "r173", "r175", "r176", "r230", "r233", "r234", "r237", "r238", "r251", "r262", "r314" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]", "negatedLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r22", "r154" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/FixedAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r156", "r336", "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "5. Fixed Assets" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/FixedAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r21", "r152" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/FixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r9", "r10", "r154", "r285", "r315", "r323" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Fixed assets, net", "verboseLabel": "Fixed Assets" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets", "http://thctherapeutics.com/role/FixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r9", "r152" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/FixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PHYSICAL SILVER ASSETS (Details Narrative)" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r203", "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r203", "r276", "r277", "r280" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r203", "r276", "r280", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r274", "r275", "r277", "r281", "r282" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "7. Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r57" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "[Repayments of Related Party Debt]", "negatedLabel": "Payments on related party advances" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r199", "r217", "r285", "r321", "r330", "r331" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "verboseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/BasisOfPresentationAndGoingConcernDetailsNarrative", "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r77", "r78", "r79", "r81", "r87", "r89", "r135", "r214", "r215", "r216", "r227", "r228", "r249", "r327", "r329" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r70", "r71" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r46", "r74", "r115", "r116", "r119", "r124", "r125", "r129", "r130", "r131", "r134", "r164", "r165", "r166", "r169", "r170", "r171", "r172", "r173", "r175", "r176", "r262", "r314" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r49" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salaries and wages" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.", "label": "Summary Of Change In Fair Value On Recurring Basis" } } }, "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule Of Convertible Notes Payable" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r247", "r248" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule Of Derivative Liabilities" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported.", "label": "Schedule Of Intangible Assets" } } }, "localname": "ScheduleOfImpairedIntangibleAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Schedule Of Fixed Assets" } } }, "localname": "ScheduleOfOtherAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/FixedAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule Of Advances From Related Affiliate" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r200", "r204" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule Of Summary Of Warrant Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/StockWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r52" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "General and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r61" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected Dividends", "verboseLabel": "Expected Dividends" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails1", "http://thctherapeutics.com/role/RelatedPartyTransactionsDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected Volatility", "verboseLabel": "Expected Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails1", "http://thctherapeutics.com/role/RelatedPartyTransactionsDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk Free Interest Rate", "verboseLabel": "Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails1", "http://thctherapeutics.com/role/RelatedPartyTransactionsDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period]", "negatedLabel": "Warrants Canceled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/StockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Warrants Granted And Assumed" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/StockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Weighted Average Exercise Price, Warrants Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/StockWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted Average Exercise Price, Warrants Canceled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/StockWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r205", "r206" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r209", "r218" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected Term (years)", "verboseLabel": "Expected Term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails1", "http://thctherapeutics.com/role/RelatedPartyTransactionsDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r69", "r76" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "3. Summary Of Significant Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r12", "r13", "r14", "r72", "r74", "r91", "r92", "r93", "r95", "r97", "r103", "r104", "r105", "r134", "r164", "r169", "r170", "r171", "r175", "r176", "r180", "r181", "r183", "r187", "r193", "r262", "r342" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets", "http://thctherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative", "http://thctherapeutics.com/role/StockWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r33", "r42", "r43", "r44", "r77", "r78", "r79", "r81", "r87", "r89", "r102", "r135", "r193", "r199", "r214", "r215", "r216", "r227", "r228", "r249", "r264", "r265", "r266", "r267", "r268", "r269", "r327", "r328", "r329", "r344" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets", "http://thctherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails", "http://thctherapeutics.com/role/FixedAssetsDetails", "http://thctherapeutics.com/role/IntangibleAssetsDetails", "http://thctherapeutics.com/role/RelatedPartyTransactionsDetails", "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative", "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative", "http://thctherapeutics.com/role/StockWarrantsDetails", "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENT OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r77", "r78", "r79", "r102", "r288" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets", "http://thctherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://thctherapeutics.com/role/ConvertibleNotesPayableDetails", "http://thctherapeutics.com/role/FixedAssetsDetails", "http://thctherapeutics.com/role/IntangibleAssetsDetails", "http://thctherapeutics.com/role/RelatedPartyTransactionsDetails", "http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative", "http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative", "http://thctherapeutics.com/role/StockWarrantsDetails", "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r17", "r18", "r74", "r133", "r134", "r262", "r285" ], "calculation": { "http://thctherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total stockholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets", "http://thctherapeutics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r73", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r199", "r201" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "12. Shareholders' Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ShareholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "13. Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit": { "auth_ref": [ "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of time deposit liabilities, including certificates of deposit, in denominations that meet or exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit.", "label": "Cash In Excess Of Fdic Limit" } } }, "localname": "TimeDepositsAtOrAboveFDICInsuranceLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r106", "r107", "r109", "r110", "r111", "r112", "r113" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/SummaryOfSignificantPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r90", "r97" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://thctherapeutics.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21564-112644" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r201": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r282": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r287": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "35", "SubTopic": "360", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=66906256&loc=d3e66150-109466" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "360", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=6475089&loc=d3e66584-109467" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "360", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=6475089&loc=d3e66610-109467" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "40", "SubTopic": "360", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=6475089&loc=d3e66625-109467" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r339": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r341": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r342": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r343": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" } }, "version": "2.1" }